Articles from Callio Therapeutics

Callio leaders delivered three presentations and two panel discussions on dual-payload ADC resistance, manufacturability, linker design, and the path to next-generation ADCs

Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipeline

Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer

SEATTLE and SINGAPORE, May 27, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced that it will present a trial-in-progress poster highlighting the Phase 1 trial design of CLIO-8221 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2) in Chicago. CLIO-8221 is a first-in-class dual-payload ADC currently in Phase 1 clinical development (NCT07300943) for HER2-expressing solid tumors.

SEATTLE and SINGAPORE, April 15, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced a poster presentation on CLIO-8221 at the American Association of Cancer Research (AACR) Annual Meeting 2026 (April 17-22, San Diego). CLIO-8221, currently being evaluated in an ongoing Phase 1 trial, is a first-in-class dual-payload ADC, engineered for targeted delivery of two payload classes, a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, to HER2-expressing tumors.

Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors